Variable | Base case | Range of sensitivity analysis |
---|---|---|
Pneumonia – Incidence | Age-specific data | -/+20% for hospitalizations |
-/+50% for ambulatory cases | ||
Pneumonia – Case fatality rate | Age-specific data | -/+20% |
AOM – Incidence | Age-specific data | -/+20% for myringotomies |
-/+50% for total cases | ||
AOM - Etiology | Country-specific data | -/+20% for Sp cases |
-/+40% for NTHi cases | ||
AOM – Etiology | Country-specific data | -/+20% for SpC cases |
Meningitis – Incidence | Age-specific data | -/+50% |
Meningitis – Case fatality rate | Age-specific data | -/+20% |
Meningitis – Risk of sequelae | Age-specific data | -/+20% |
Bacteremia – Incidence | Age-specific data | -/+50% |
Bacteremia – Case fatality rate | Age-specific data | -/+20% |
ID - Etiology (Sp serotype distribution) | Age-specific data | 95% CI |
ID - Etiology (Sp in ≥10 years) | Age-specific data | -/+20% |
Effectiveness in reducing hospitalizations for pneumonia | 25% | 95% CI |
Effectiveness in reducing ambulatory pneumonia | 4,3% | 95% CI |
Efficacy in preventing AOM according to type of pathogen (SpC, SpNC y HiNT) | 57.6% for SpC | 95% CI |
-33% for SpNC | ||
35.3% for NTHi | ||
Efficacy in preventing ID | Based on efficacy by serotype for PCV-7 | 95%CI for each serotype |
Costs of administration and vaccine wastage* | 1 dollar with 10% wastage | -/+20% |
Direct cost of treatment of acute events | Disease-specific data | -/+20% |
Annual cost of long term treatment of sequelae | Data specific for each condition | -/+20% |
Disutilities associated with AOM (with and without myringotomy) | Data specific for each condition | 95% CI |
†Disutilities associated with acute diseases except AOM†| Data specific for each condition | 95% CI |
Disutilities associated with chronic conditions (sequelae)‡ | Data specific for each condition | 95% CI |